Bavdegalutamide(PROTAC雄激素受体降解剂)治疗转移性去势抵抗性前列腺癌的I/II期研究
本I/II期研究评估了PROTAC雄激素受体降解剂bavdegalutamide在经AR通路抑制剂治疗的mCRPC患者中的安全性和疗效。I期确定RP2D为420mg每日一次;II期显示AR T878/H875突变患者PSA50率达60.0%,中位rPFS 11.1个月,安全性总体可控。
要点
- AR T878/H875突变mCRPC患者PSA50率60.0%,中位rPFS 11.1个月。
- 野生型/其他AR变异及AR L702H/AR-V7亚组PSA50率低(4.3%和3.1%)。
- II期患者3级TRAE发生率17.4%,无≥4级TRAE。
核心结论
- Bavdegalutamide安全性可控,在mCRPC尤其AR T878/H875突变患者中显示有前景的临床活性。
研究设计与样本
- I/II期研究,纳入既往接受ARPI的成年男性mCRPC患者;I期剂量递增确定RP2D,II期按RP2D给药(28天周期)。
- I期95例确定RP2D为420mg每日一次;II期144例评估疗效与安全性。
主要发现
- II期AR T878和/或H875突变组(n=20)PSA50率60.0%、PSA30率70.0%,中位rPFS 11.1个月。
- 野生型AR或其他AR改变组(n=46)PSA50率4.3%、PSA30率6.5%,中位rPFS 4.2个月。
- AR L702H突变或AR剪接变异7表达组(n=32)PSA50率3.1%、PSA30率6.3%,中位rPFS 5.1个月。
- 较少预处理亚组(n=42,仅一种ARPI且未化疗)PSA50率21.4%、PSA30率23.8%,中位rPFS 11.1个月。
- II期患者72.3%发生1/2级TRAE,17.4%发生3级TRAE,无≥4级TRAE;TRAE导致减量和停药分别占11.8%和11.1%。
关键数值与推荐
- RP2D为bavdegalutamide 420mg每日一次口服。
- PSA反应定义为较基线下降≥50%(PSA50)或≥30%(PSA30)。
临床怎么用
- 对于携带AR T878/H875突变的mCRPC患者,bavdegalutamide可能提供具有临床意义的PSA反应和rPFS获益。
- 治疗期间需监测TRAE,部分患者需减量或停药。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This phase I/II study (which, to our knowledge, is the first such study in humans) evaluated the safety and efficacy of bavdegalutamide (ARV-110), a proteolysis-targeting chimera (PROTAC) androgen receptor (AR) degrader, in patients with metastatic castration-resistant prostate cancer (mCRPC). PATIENTS AND METHODS: Eligible patients were adult (18 years and older) males with mCRPC previously treated with an AR pathway inhibitor (ARPI). In phase I, patients received escalating doses of oral bavdegalutamide to determine the recommended phase II dose (RP2D). In phase II, patients received bavdegalutamide at the RP2D in 28-day cycles. Antitumor activity, including prostate-specific antigen (PSA) response rate (≥50% [PSA50] or ≥30% [PSA30] decline from baseline) and radiographic progression-free survival (rPFS), was assessed in three AR molecular profile-defined subgroups and a less-pretreated (one prior ARPI without prior chemotherapy) subgroup. RESULTS: In phase I (N = 95), bavdegalutamide 420 mg once daily was the RP2D. In phase II, PSA50 and PSA30 rates, respectively, were 60.0% and 70.0% among patients with tumors harboring AR T878 and/or H875 mutations (n = 20), 4.3% and 6.5% among those with wild-type AR or other AR alterations (n = 46), and 3.1% and 6.3% among those with AR L702H mutations or AR splice variant 7 expression (n = 32); the median rPFS was 11.1, 4.2, and 5.1 months in the respective subgroups. Among less-pretreated patients (n = 42), the PSA50 rate was 21.4%, the PSA30 rate was 23.8%, and the median rPFS was 11.1 months. Among phase II patients (n = 144), 72.3% experienced grade 1/2 treatment-related adverse events (TRAEs) and 17.4% experienced grade 3 TRAEs; no grade ≥4 TRAEs occurred. TRAEs led to dose reduction and discontinuation in 11.8% and 11.1% of patients, respectively. CONCLUSION: Bavdegalutamide had a manageable safety profile and showed promising clinical activity in patients with mCRPC, particularly those with tumors harboring AR T878/H875 mutations.
引用
- Gao X, Garmezy B, Vuky J, et al. Phase I/II Study of Bavdegalutamide, a Proteolysis-Targeting Chimera Androgen Receptor Degrader, in Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol. 2026. PMID: 42854175. doi:10.1200/JCO-25-02995
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。